Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 64405 | 3.64 |
09:33 ET | 15284 | 3.68 |
09:35 ET | 3002 | 3.675 |
09:37 ET | 11400 | 3.685 |
09:39 ET | 24337 | 3.68 |
09:42 ET | 3800 | 3.685 |
09:44 ET | 9536 | 3.6503 |
09:46 ET | 17586 | 3.64 |
09:48 ET | 12390 | 3.64 |
09:50 ET | 12600 | 3.64 |
09:51 ET | 7390 | 3.655 |
09:53 ET | 57823 | 3.63 |
09:55 ET | 134958 | 3.605 |
09:57 ET | 18393 | 3.63 |
10:00 ET | 2300 | 3.6257 |
10:02 ET | 27921 | 3.61 |
10:04 ET | 9384 | 3.63 |
10:06 ET | 23943 | 3.63 |
10:08 ET | 27343 | 3.63 |
10:09 ET | 19567 | 3.63 |
10:11 ET | 26626 | 3.645 |
10:13 ET | 485 | 3.645 |
10:15 ET | 10696 | 3.6399 |
10:18 ET | 70999 | 3.655 |
10:20 ET | 3105 | 3.653898 |
10:22 ET | 73313 | 3.685 |
10:24 ET | 25944 | 3.67 |
10:26 ET | 13173 | 3.675 |
10:27 ET | 48102 | 3.675 |
10:29 ET | 50803 | 3.685 |
10:31 ET | 13066 | 3.68 |
10:33 ET | 68990 | 3.69 |
10:36 ET | 109954 | 3.7 |
10:38 ET | 75191 | 3.7054 |
10:40 ET | 49873 | 3.705 |
10:42 ET | 474148 | 3.735 |
10:44 ET | 65238 | 3.765 |
10:45 ET | 48545 | 3.76 |
10:47 ET | 5301 | 3.755 |
10:49 ET | 12888 | 3.75 |
10:51 ET | 11849 | 3.753896 |
10:54 ET | 3348 | 3.755 |
10:56 ET | 43872 | 3.74 |
10:58 ET | 18727 | 3.74 |
11:00 ET | 9848 | 3.725 |
11:02 ET | 13639 | 3.715 |
11:03 ET | 7004 | 3.72 |
11:05 ET | 11120 | 3.71 |
11:07 ET | 6150 | 3.71 |
11:09 ET | 4609 | 3.7049 |
11:12 ET | 13793 | 3.7 |
11:14 ET | 20588 | 3.69 |
11:16 ET | 21982 | 3.705 |
11:18 ET | 12152 | 3.6999 |
11:20 ET | 7826 | 3.7 |
11:21 ET | 12782 | 3.6889 |
11:23 ET | 1262 | 3.69 |
11:25 ET | 4700 | 3.68 |
11:27 ET | 42655 | 3.69 |
11:30 ET | 7650 | 3.69 |
11:32 ET | 14783 | 3.685 |
11:34 ET | 400 | 3.69 |
11:36 ET | 2200 | 3.69 |
11:38 ET | 1750 | 3.69 |
11:39 ET | 3574 | 3.6889 |
11:41 ET | 1600 | 3.685 |
11:43 ET | 4100 | 3.6892 |
11:45 ET | 3871 | 3.68 |
11:48 ET | 16574 | 3.6892 |
11:50 ET | 700 | 3.685 |
11:52 ET | 6100 | 3.68 |
11:54 ET | 1800 | 3.685 |
11:56 ET | 111230 | 3.705 |
11:57 ET | 44325 | 3.72 |
11:59 ET | 13563 | 3.725 |
12:01 ET | 463879 | 3.71 |
12:03 ET | 50863 | 3.72 |
12:08 ET | 700 | 3.7288 |
12:10 ET | 750 | 3.73 |
12:12 ET | 4000 | 3.73 |
12:14 ET | 10228 | 3.705 |
12:15 ET | 5938 | 3.7061 |
12:17 ET | 4006 | 3.705 |
12:19 ET | 11927 | 3.71 |
12:21 ET | 185630 | 3.74 |
12:24 ET | 11927 | 3.725 |
12:26 ET | 200 | 3.73 |
12:28 ET | 10872 | 3.735 |
12:30 ET | 3700 | 3.735 |
12:32 ET | 6845 | 3.735 |
12:33 ET | 6676 | 3.735 |
12:35 ET | 7264 | 3.735 |
12:37 ET | 950 | 3.735 |
12:39 ET | 3300 | 3.74 |
12:42 ET | 14018 | 3.735 |
12:44 ET | 37293 | 3.72 |
12:46 ET | 11408 | 3.705 |
12:48 ET | 50693 | 3.7 |
12:50 ET | 5245 | 3.7 |
12:51 ET | 12502 | 3.705 |
12:53 ET | 4302 | 3.705 |
12:55 ET | 7113 | 3.7 |
12:57 ET | 11033 | 3.705 |
01:00 ET | 3100 | 3.7 |
01:02 ET | 501547 | 3.71 |
01:04 ET | 22002 | 3.69 |
01:06 ET | 14375 | 3.71 |
01:08 ET | 16624 | 3.7093 |
01:09 ET | 7600 | 3.7059 |
01:11 ET | 2900 | 3.7 |
01:13 ET | 3800 | 3.705 |
01:15 ET | 12489 | 3.69 |
01:18 ET | 30810 | 3.705 |
01:20 ET | 1817 | 3.7082 |
01:22 ET | 16505 | 3.705 |
01:24 ET | 16507 | 3.705 |
01:26 ET | 7277 | 3.705 |
01:27 ET | 6685 | 3.7 |
01:29 ET | 4674 | 3.705 |
01:31 ET | 6376 | 3.705 |
01:33 ET | 7506 | 3.7 |
01:36 ET | 7405 | 3.7 |
01:38 ET | 22893 | 3.695 |
01:40 ET | 1373 | 3.695 |
01:42 ET | 18884 | 3.71 |
01:44 ET | 21043 | 3.71 |
01:45 ET | 2400 | 3.71 |
01:47 ET | 3500 | 3.705 |
01:49 ET | 20083 | 3.715 |
01:51 ET | 31729 | 3.71 |
01:54 ET | 43733 | 3.73 |
01:56 ET | 57823 | 3.745 |
01:58 ET | 26001 | 3.755 |
02:00 ET | 63750 | 3.77 |
02:02 ET | 16888 | 3.78 |
02:03 ET | 95136 | 3.775 |
02:05 ET | 17110 | 3.785 |
02:07 ET | 3800 | 3.79 |
02:09 ET | 4659 | 3.79 |
02:12 ET | 30352 | 3.785 |
02:14 ET | 72016 | 3.765 |
02:16 ET | 7750 | 3.77 |
02:18 ET | 6000 | 3.765 |
02:20 ET | 5642 | 3.765 |
02:21 ET | 13257 | 3.7654 |
02:23 ET | 24882 | 3.765 |
02:25 ET | 3903 | 3.76 |
02:27 ET | 5774 | 3.765 |
02:30 ET | 2400 | 3.76 |
02:32 ET | 5110 | 3.765 |
02:34 ET | 3014 | 3.7695 |
02:36 ET | 358573 | 3.765 |
02:38 ET | 77286 | 3.77 |
02:39 ET | 23676 | 3.765 |
02:41 ET | 274408 | 3.77 |
02:43 ET | 30857 | 3.775 |
02:45 ET | 28430 | 3.765 |
02:48 ET | 9488 | 3.76 |
02:50 ET | 22179 | 3.765 |
02:52 ET | 94454 | 3.755 |
02:54 ET | 1000 | 3.75 |
02:56 ET | 8404 | 3.76 |
02:57 ET | 2257 | 3.755 |
02:59 ET | 3005 | 3.755 |
03:01 ET | 3672 | 3.755 |
03:03 ET | 34561 | 3.77 |
03:06 ET | 12187 | 3.765 |
03:08 ET | 47768 | 3.77 |
03:10 ET | 2670 | 3.77 |
03:12 ET | 52163 | 3.775 |
03:14 ET | 60469 | 3.775 |
03:15 ET | 26661 | 3.765 |
03:17 ET | 1301 | 3.76 |
03:19 ET | 2550 | 3.77 |
03:21 ET | 13386 | 3.78 |
03:24 ET | 15509 | 3.785 |
03:26 ET | 4251 | 3.785 |
03:28 ET | 5545 | 3.785 |
03:30 ET | 171518 | 3.8 |
03:32 ET | 21177 | 3.8 |
03:33 ET | 13429 | 3.8 |
03:35 ET | 265265 | 3.825 |
03:37 ET | 220810 | 3.84 |
03:39 ET | 357412 | 3.815 |
03:42 ET | 191374 | 3.855 |
03:44 ET | 48117 | 3.845 |
03:46 ET | 35188 | 3.8498 |
03:48 ET | 63176 | 3.83 |
03:50 ET | 231808 | 3.845 |
03:51 ET | 250556 | 3.845 |
03:53 ET | 141861 | 3.85 |
03:55 ET | 524021 | 3.825 |
03:57 ET | 419406 | 3.8 |
04:00 ET | 2440055 | 3.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -11.7x | --- |
CG Oncology Inc | 2.2B | -27.9x | --- |
Soleno Therapeutics Inc | 2.2B | -15.6x | --- |
Keros Therapeutics Inc | 2.3B | -10.4x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -26.7x | --- |
NewAmsterdam Pharma Company NV | 2.3B | -11.0x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $29.5M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.32 |
Book Value | $0.46 |
P/E Ratio | -11.7x |
Price/Sales (TTM) | 74.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -705.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.